Category: Uncategorized

  Algernon Pharmaceuticals Inc. CEO Christopher J. Moreau and guest Dr. David Nutt, renowned neuropsychopharmacologist and DMT consultant discuss the Company’s upcoming Phase 1 study of DMT for Stroke. Live Interview – July 8, 2021 …

  Algernon Pharmaceuticals (CSE: AGN – OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive to share news that the company has reached 70% enrollment for its Phase 2 clinical study of its re-purposed drug Ifenprodil for idiopathic pulmonary fibrosis (IPF) and chronic cough. Mr. Moreau explains to Proactive how the trial is taking parts at six sites in total with four located in Australia and two in New Zealand. The Phase 2 trial lasts 12 weeks total for patients. …

Finding an effective method of preventing the possibility of stroke is something that medical science has grappled with for decades. Now, Algernon Pharmaceuticals, a clinical stage biopharmaceutical development company, looks to be making significant headway by repurposing a known psychedelic compound that is part of the tryptamine family to help battle stroke. The Stockhouse interview with Algernon CEO Christopher J. Moreau has been broken down into four separate segments for your convenience Part 1 CEO Christopher J. Moreau begins the interview with a short introduction to the Company and provides an explanation for DMT as a clinical drug.   Part …

Algernon Pharmaceuticals Launches Ifenprodil Pancreatic Cancer Clinical Research Program     Algernon Pharmaceuticals (CSE: AGN – OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive to share news that the Company will be looking at their drug Ifenprodil in a new clinical research program for Pancreatic Cancer. Mr. Moreau explains to Proactive how Ifenprodil demonstrated a significant anti-tumour effect in an animal model which was reported in a paper published in the Dove Press Journal, Clinical Pharmacology: Advances and Applications. That report stated that Ifenprodil significantly and rapidly reduced the average solid tumour size by approximately 50%. …

Could the ‘spirit molecule’ be a treatment option for stroke? Researchers have spent decades and billions of dollars unsuccessfully searching for novel treatments for stroke. Now a Vancouver-based company is putting a unique hypothesis to the test. By Sam Riches In February, Algernon Pharmaceuticals announced it was planning to be the first company in the world to test DMT in human clinical trials for stroke. Photo by Gorodenkoff / iStock / Getty Images About every 10 minutes, someone in Canada has a stroke. Stroke is the leading cause of adult disability in the country and the third leading cause of …

  Rick Strassman is an American clinical associate professor of psychiatry at the University of New Mexico School of Medicine. He has held a fellowship in clinical psychopharmacology research at the University of California San Diego and was Professor of Psychiatry for eleven years at the University of New Mexico. In the early 90’s, Dr. Strassman was the first person in the United States to conduct clinical human research with DMT in more than 20 years. Dr. Strassman is also the author of DMT: The Spirit Molecule, which summarizes his academic research on DMT and includes his own reflections and conclusions …

Algernon Pharmaceutical’s DMT Clinical Research Program for Stroke Receives Positive FDA Feedback     Algernon Pharmaceuticals (CSE: AGN – OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive to discuss the Company’s response from the FDA in regard to Algernon Pharmaceuticals investigating the use of DMT in the rehabilitation of stroke. Mr. Moreau explains to Proactive how the FDA provided valuable input into the design of the Company’s planned Phase 1 clinical trial, which will be conducted through Hammersmith Medicines Research in the UK, in Q4-2021. …

PRMediaNow Algernon Pharmaceuticals Update with CEO Christopher Moreau   Interview with Christopher Moreau, CEO of Algernon Pharmaceuticals with host Cyndi Edwards of PRMediaNow regarding the announcement that Ifenprodil has reduced Interleukin 6 with statistical significance in its recent Ifenprodil Phase 2b/3 COVID-19 study. …

Algernon Pharmaceuticals has now enrolled 50% of patients for its Ifenprodil IPF/Chronic Cough study and announces that Ifenprodil has reduced Interleukin 6 (IL-6) with statistical significance in its recent Ifenprodil Phase 2b/3 COVID-19 trial. Algernon Pharmaceuticals (CSE: AGN – OTCQB: BTHCF) – CEO Christopher Moreau of Algernon Pharmaceuticals joins Steve Darling from Proactive to discuss the announcement that Ifenprodil has reduced Interleukin 6 with statistical significance in its recent Ifenprodil Phase 2b/3 COVID-19 trial. This is key information for the ongoing Phase 2 trial of Ifenprodil for idiopathic pulmonary fibrosis and chronic cough taking place in Australia and New Zealand. …

Psychedelic Finance – Interview with Professor David Nutt | Algernon Pharmaceuticals DMT Stroke Consultant David Nutt is a psychiatrist and the Edmond J. Safra Professor of Neuropsychopharmacology in Imperial College London. He has been president of the European Brain Council, the BAP, BNA, and ECNP. He is currently Founding Chair of the charity DrugScience.org.uk. David has published 35 books and over 1000 papers, including in Nature, Cell Lancet and New England Journal of Medicine. These define his many landmark contributions to psychopharmacology including GABA and noradrenaline receptor function in anxiety disorders, serotonin function in depression, endorphin and dopamine function in …